Boehringer announced that the FDA approved new labeling for Stiolto Respimat (tiotropium bromide & olodaterol) Inhalation Spray that includes data...
The FDA approved a sNDA for Stiolto Respimat (olodaterol + tiotropium), from Boehringer, that adds data showing improvement in health-related...
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
Boehringer has announced the publication of data that show Stiolto Respimat (olodaterol + tiotropium) improved lung function across a range...
Boehringer announced the first results from the Phase IIIb/IV PHYSACTO trial that showed Stiolto Respimat (olodaterol + tiotropium) combined with...
Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range...
Boehringer Ingelheim has announced new data that show increase in FEV1 AUC0–12, a measure of lung function, with Stiolto Respimat...
Boehringer Ingelheim has announced new data analyses from the pivotal Phase III TONADO 1&2 studies, which explored the efficacy and...
Boehringer Ingelheim announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance...